Anti-obesity Treatments 2007-2012 - A Blockbuster Target Market

By Author: Bharat Book Bureau
Total Articles: 1486
Comment this article

By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, researcher has found. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities.

This high-level management report examines the commercial prospects for anti-obesity prescription drugs in the global healthcare market. With obesity now the most common nutritional disorder in western industrialised countries, is your company's pipeline showing the potential blockbuster the market offers? Obesity in the US and Europe has already reached high levels, with obesity being described as an epidemic and a public health time-bomb. Government funding continues to increase, especially in the most seriously affected areas - the US and Europe.

The U.S. health panel's rejection of Sanofi-Aventis' obesity drug Zimulti however has cast a shadow over other experimental products in the same class while offering a stark reminder of challenges facing the development of weight-loss medications. The Food and Drug Administration ...
... advisory panel on Wednesday unanimously recommended Zimulti not be approved because of concerns it may increase suicidal thinking and depression. The FDA is expected to make a final decision by July 26.

Obesity is an major risk factor for serious, chronic diseases such as type 2 diabetes, heart disease, stroke and certain cancers. In addition, obese people are more likely to suffer from psychological problems and a poorer quality of life in general. The increase in obesity during recent decades involves a complex interplay of environmental, social, economic, genetic and behavioural factors. Its most prominent causes include unhealthy modern diets - high in sugars and fats - and reduced physical activity.

New drugs in the field have the potential to treat a range of conditions associated with metabolic syndrome, with high potential revenues and life cycle benefits. It concludes that the commercial opportunities for anti-obesity medications are significant, predicting multi-billion revenues for the anti-obesity segment by early next decade. Nevertheless, there are many hurdles that market participants will have to overcome, particularly convincing healthcare authorities and practitioners that the drugs have adequate efficacy, safety and cost-effectiveness.

Anti-Obesity Treatments 2007-2012, examines the market for anti-obesity drugs critically, through comprehensive primary and secondary research. In addition to consultation with experts in medical practice, academia and industry, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=52065

bharatbook.com, a leading information aggregator, facilitates and supports the business information needs for market research , corporate / strategic planning by providing the latest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management, country intelligence, consumer & durable goods, chemical and more. With over 90,000 reports, you can get instant access and insights on the studies in your areas of interest. Contact us at +91 22 27578668 / 27579438 or email info@bharatbook.com or our website www.bharatbook.com